Financial reports
ARS
2023 FY
Annual report to shareholders
1 Apr 24
10-K
2023 FY
Annual report
11 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
10-K
2022 FY
Annual report
17 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
Current reports
8-K
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 Feb 24
8-K
Other Events
11 Jan 24
8-K
Other Events
11 Dec 23
8-K
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
14 Nov 23
8-K
Capricor Therapeutics Announces $23 Million Registered Direct Offering
29 Sep 23
8-K
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy
29 Sep 23
8-K
Capricor Therapeutics Appoints Michael Kelliher to Board of Directors
6 Sep 23
8-K
Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7 Aug 23
8-K
Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors
24 Jul 23
8-K
Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors
13 Jul 23
Registration and prospectus
S-8
Registration of securities for employees
16 Feb 24
424B5
Prospectus supplement for primary offering
29 Sep 23
FWP
Free writing prospectus
29 Sep 23
S-8
Registration of securities for employees
30 Jan 23
S-8
Registration of securities for employees
17 Feb 22
424B5
Prospectus supplement for primary offering
21 Jun 21
S-3/A
Shelf registration (amended)
15 Jun 21
S-3
Shelf registration
16 Mar 21
S-8
Registration of securities for employees
12 Feb 21
S-8
Registration of securities for employees
17 Jun 20
Proxies
DEF 14A
Definitive proxy
29 Mar 24
PRE 14A
Preliminary proxy
20 Mar 24
DEF 14A
Definitive proxy
17 Apr 23
PRE 14A
Preliminary proxy
7 Apr 23
DEF 14A
Definitive proxy
12 Apr 22
DEF 14A
Definitive proxy
20 Apr 21
DEF 14A
Definitive proxy
17 Apr 20
DEF 14A
Definitive proxy
30 Apr 19
PRE 14A
Preliminary proxy
19 Apr 19
DEF 14A
Definitive proxy
26 Apr 18
Other
EFFECT
Notice of effectiveness
17 Jun 21
CORRESP
Correspondence with SEC
15 Jun 21
CORRESP
Correspondence with SEC
14 Jun 21
UPLOAD
Letter from SEC
19 Mar 21
EFFECT
Notice of effectiveness
20 May 20
CORRESP
Correspondence with SEC
15 May 20
UPLOAD
Letter from SEC
14 May 20
EFFECT
Notice of effectiveness
18 Dec 19
CORRESP
Correspondence with SEC
13 Dec 19
UPLOAD
Letter from SEC
9 Dec 19
Ownership
4
EARL M COLLIER JR
25 Apr 24
4
David B Musket
24 Apr 24
SC 13G
HIGHBRIDGE CAPITAL MANAGEMENT LLC
7 Feb 24
4
Mike Kelliher
4 Jan 24
4
Philip J Gotwals
4 Jan 24
4
Paul Gisbert Auwaerter
4 Jan 24
4
David B Musket
4 Jan 24
4
GEORGE W DUNBAR JR
4 Jan 24
4
Karimah Es Sabar
4 Jan 24
4
EARL M COLLIER JR
4 Jan 24